MIDRIX-LUNG-002 clinical trials

A phase 1b study of an autologous dendritic cell immunotherapy in combination with anti-programmed death-1 treatment in patients with metastatic non-small-cell lung cancer (DARE-LUNG)

This study is looking at a new way to treat an advanced form of lung cancer. It combines a special vaccine made from your own cells with an existing cancer medicine to see if it helps reduce side effects and works better.